Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study. Issue 12 (31st December 2021)

• Record Type: Journal Article
• Authors: Wallace, Arthur W; Cirillo, Piera M; Ryan, James C; Krigbaum, Nickilou Y; Badathala, Anusha; Cohn, Barbara A
• Is Part Of: BMJ open. Volume 11:Issue 12(2021)
• Publication Date: 2021-12-31
• Subjects: COVID-19 -- epidemiology -- public health; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-050051
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: SARS-CoV-2 enters cells using the ACE2 receptor. Medications that affect ACE2 expression or function such as angiotensin receptor blockers (ARBs) and ACE inhibitors (ACE-I) and metformin have the potential to counter the dysregulation of ACE2 by the virus and protect against viral injury. Here, we describe COVID-19 survival associated with ACE-I, ARB and metformin use. Design: This is a hospital-based observational study of patients with COVID-19 infection using logistic regression with correction for pre-existing conditions and propensity score weighted Cox proportional hazards models to estimate associations between medication use and mortality. Setting: Medical record data from the US Veterans Affairs (VA) were used to identify patients with a reverse transcription PCR diagnosis of COVID-19 infection, to classify patterns of ACE inhibitors (ACE-I), ARB, beta blockers, metformin, famotidine and remdesivir use, and, to capture mortality. Participants: 9532 hospitalised patients with COVID-19 infection followed for 60 days were analysed. Outcome measure: Death from any cause within 60 days of COVID-19 diagnosis was examined. Results: Discontinuation of ACE-I was associated with increased risk of death (OR: 1.4; 95% CI 1.2–1.7). Initiating (OR: 0.3; 95% CI 0.2–0.5) or continuous (OR: 0.6; 95% CI 0.5–0.7) ACE-I was associated with reduced risk of death. ARB and metformin associations were similar in direction and magnitude and also statistically significant. Results were unchanged when accounting for pre-existing morbidity and propensity score adjustment. Conclusions: Recent randomised clinical trials support the safety of continuing ACE-I and ARB treatment in patients with COVID-19 where indicated. Our study extends these findings to suggest a possible COVID-19 survival benefit for continuing or initiating ACE-I, ARB and metformin medications. Randomised trials are appropriate to confirm or refute the therapeutic potential for ACE-I, ARBs and metformin.